Guidelines for the therapeutic use of botulinum toxin in movement disorders

Neurological Sciences

Volumn 18, Issue 5, 1997, Pages 261-269

  Berardelli, A ^a,b   Abbruzzese, G ^a   Bertolasi, L ^a   Cantarella, G ^a   Carella, F ^a   Curra A ^a   De Grandis, D ^a   DeFazio, G ^a   Galardi, G ^a   Girlanda, P ^a   Livrea, P ^a   Modugno, N ^a   Priori, A ^a   Ruoppolo, G ^a   Vacca, L ^a   Manfredi, M ^a  

^a Italian Society of Neurology   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Botulinum toxin; Movement disorders; Treatment, dystonia, spasticity, tremor, cramps

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN;

ARM MUSCLE; BLEPHAROSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; ESSENTIAL TREMOR; HEMIFACIAL SPASM; HUMAN; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; LARYNX MUSCLE; LEG MUSCLE; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE WEAKNESS; NECK MUSCLE; PAIN; REVIEW; SPASTICITY; STUTTERING; TIC; TREMOR;

BOTULINUM TOXINS; HUMANS; MOVEMENT DISORDERS;

EID: 0031424647     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02083302     Document Type: Review

References (74)

1. ALBANESE A, BENTIVOGLIO AR, COLOSIMO C et al. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J Neurol Neurosurg Psychiatry, 1996; 61: 693-694.
2. ARAMIDEH M, ONGERBOER DE VISSER BW, DEVRIESE BB et al. Electromyographic features of levator palpebrae superioris and orbicularis oculi muscle in blepharospasm. Brain, 1994; 117: 27-38.
3. ARAMIDEH M, ONGERBOER DE VISSER BW, KOHELMAN JHTM et al. Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure. Mov Disord, 1994; 9: 395-402.
4. ARAMIDEH M, ONGERBOER DE VISSER BW, BRANS JMW et al. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry, 1995; 59: 309-311.
5. ARONSON AE, BROWN JR, LITIN EM et al. Spastic Dysphonia II. Comparison with Essential (voice) Tremor and other neurologic dysphonias. J Speech Hear Disord, 1968; 33: 219-231.
6. BERARDELLI A, FORMICA A, MERCURI B et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorders Study Group. Ital J Neurol Sci, 1993; 14: 361-368.
7. BERARDELLI A, MERCURI B, PRIORI A. Botulinum toxin for facial-oral-mandibular spasms and bruxism. In: Jankovic J, Hallett M (eds). Therapy with Botulinum Toxin. Marcel Dekker, Inc., New York, 1994: 361-367.
8. BERTOLASI L, PRIORI A, TOMELLERI G, et al. Botulinum toxin treatment of muscle cramps: a clinical and neurophysiological study. Ann Neurol, 1997; 41: 181-186
9. BHAKTA BB, COZENS JA, BAMFORD JM, CHAMBERLAIN MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry, 1996; 61:30-35.
10. BLACKIE JD, LEES AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry, 1990; 53: 640-643.
11. BLITZER A, BRIN MF, STEWART C, AVIV JE, FAHN S. Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope, 1992; 102:163-167.
12. BRIN MF, STEWART C, BLITZER A, DIAMOND B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology, 1994; 44: 2262-2266.
13. BORODIC GE, FERRANTE R, WIEGNER AW, YOUNG RR. Treatment of spasticity with botulinum toxin. Ann Neurol, 1992; 31: 113.
14. BORODIC GE, PEARCE LB, SMITH K, JOSEPH M. Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck, 1992; 14: 33-37.
15. BORODIC GE, FERRANTE R, PEARCE BL, SMITH K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A-toxin injections. Mov Disord, 1994; 9: 31-39.
16. BRANS JWM, LINDEBOON R, SNOEK JW et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology, 1996; 46: 1066-1072.
17. BRIN MF, FAHN S, MOSKOWITS C et al. Localized injections of botulinum toxin for the treatment of focal dystonias and hemifacial spasm. Mov Disord, 1987; 8:1-20.
18. BURBAUD P, WIART JL, GAUJARD E et al. A randomized, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry, 1996; 61: 265-268.
19. COMELLA C, BUCHMAN A, TANNER C, BROWN-TOMS NC, GOETZ CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology, 1992; 42: 878-882.
20. COLE R, HALLET M, COHEN LG. Double-blind trial toxin for treatment of focal hand dystonia. Mov Disord, 1995; 4: 466-471.
21. CRUCCU G, INGHILLERI M, BERARDELLI A et al. Pathophysiology of hemimasticatory spasm. J Neurol Neurosurg Psychiatry, 1994; 57: 43-50.
22. DAS TK, PARK DM. Botulinum toxin in treating spasticity. Br J Clin Pract, 1989; 43: 401-402.
23. DENGLER R, NEYER U, WOHLFARTH K, BETTIG U, JANZIK HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol, 1992; 239: 375-378.
24. DEUSCHL G, LÖHLE E. Botulinum toxin treatment of palatal tremor (myoclonus). In: Jankovic J, Hallett M (eds). Therapy with Botulinum Toxin. Marcel Dekker, Inc., New York, 1994: 567-576.
25. DUNNE JW, HEYE N, DUNNE SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry, 1995; 58: 232-235.
26. ELSTON JS. A new variant of blepharospasm. J Neurol Neurosurg Psychiatry, 1992; 55: 369-371.
27. [27 ELSTON JS. Idiopathic blepharospasm, hemifacial spasm and therapeutic ptosis induction. In: P. Moore (ed) Handbook of botulinum toxin treatment. Blackwell Science, 1995: 90-102.
28. ESTEBAN A, GIMENEZ ROLDAN S. Involuntary closure of eyelids in parkinsonism. Electrophysiological evidence for prolonged inhibition of the levator palpebrae muscles. J Neurol Sci, 1988; 85: 333-345.
29. FAHN S. Assessment of primary dystonias. In: Mumsaj TL (ed). Quantification of Neurologic Deficit. Butterworths, 1989: 241-270.
30. FAHN S, LIST T, MOSKOWITZ C et al. Double blind controlled study of botulinum toxin for blepharospasm. Neurology, 1985; 35: 271-272.
31. GARNER CG, STRAUBE A, WITT TN, GASSER T, OERTEL WH. Time course of distant effects of local injections of botulinum toxin. Mov Disord, 1993; 8: 33-37.
32. GREENE P, KANG U, FAHN S, BRIN M, MOSKOWITZ RN, FLASTER E. Double blind, placebo controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology, 1990; 40: 1213-1218.
33. GREENE P, FAHN S, DIAMOND B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord, 1994; 9: 213-217.
34. GRAZKO MA, POLO KB, JABBARI B. Botulinum toxin A for spasticity, muscle spasm, and rigidity. Neurology, 1995; 45: 712-717.
35. HESSE S, LUCKE D, MALEZIC M et al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry, 1994; 57: 1321-1324.
36. HESSE S, JAHNKE MT, LUECKE D, MAURITZ KH. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett, 1995; 201: 37-40.
37. HESSE S, KRAJINIK J, LUECKE D, JAHNKE MT, GREGORIC M, MAURITZ KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke, 1996; 27: 455-460.
38. JANKOVIC J, OMAN J. Botulinum A toxin for cranial cervical dystonia: a double blind placebo controlled study. Neurology, 1987; 37: 616-623.
39. JANKOVIC J, SCHWARTZ K, DONOVAN DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other facial dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry, 1990; 53: 633-639.
40. JANKOVIC J, BRIN MF. Therapeutic uses of botulinum toxin. New Engl J Med, 1991; 324: 1186-1194.
41. JANKOVIC J, SCHWARTZ K. Botulinum Toxin treatment of tremors. Neurology, 1991; 41: 1185-1188.
42. JANKOVIC J. Botulinum toxin in movement disorders. Curr Opin in Neurology, 1994; 7: 358-366.
43. JANKOVIC J. Botulinum toxin in the treatment of tics. In: Jankovic J, Hallett M (eds). Therapy with Botulinum Toxin, Marcel Dekker, New York, 1994: 503-509.
44. JANKOVIC J, SCHWARTZ K, CLEMENCE W, ASWAD A, MOEDAUNT J. A randomized, double blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord, 1996; 11: 250-256.
45. KARP BI, COLE RA, COHEN LG, GRILL S, LOU JS, HALLETT M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology, 1994; 44: 70-76.
46. LEPORE FE, DUVOISIN RC. Apraxia of eyelid opening: an involuntary levator inhibition. Neurology, 1985; 35: 423-427.
47. LEPORE V, DEFAZIO G, ACQUISTAPACE D et al. Botulinum A toxin for the so called apraxia of eyelid opening. Mov Disord, 1995; 10: 525-526.
48. LORENTZ IT, SUBRAMANIAM SS, YIANNIKAS C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double blind study on twenty-three patients. Mov Disord, 1991; 6: 145-150.
49. LUDLOW CL, BAGLEY JA, YIN SG, et al. A comparison of different injection technique in the treatment of spasmodic dysphonia with botulinum toxin. J Voice, 1992; 6: 380-386.
50. MARSDEN CD, SCHACHTER M. Assessment of extrapyramidal disorders. Br J Clin Pharmacol, 1981; 11: 129-151.
51. MEZAKI T, KAJI R, KOHARA K et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double blind, controlled study. Neurology. 1995; 45: 506-508.
52. MOORE AP, BLUMHARDT LD. A double blind trial of botulinum toxin A in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry, 1991; 54: 813-816.
53. MOORE AP. General and clinical aspects of treatment of botulinum toxin. In: Moore P. (ed.). Handbook of botulinum toxin treatment. Blackwell Science, 1995: 28-53.
54. PORTER JD, BURNS LA, MAY PJ. Morphological substrate for eyelid movements: innervation and structure of primate levator palpebrae superioris and orbicularis oculi muscles. J Comp Neurol, 1989; 287: 64-81.
55. PRIORI A, BERARDELLI A, MERCURI B, MANFREDI M. Physiological effects by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscle. Brain, 1994; 118: 801-807.
56. PULMANN SL, GREENE P, FAHN S, PEDERSEN SF. Approach to the treatment of limb Disorders with Botulinum Toxin A. Arch Neurol, 1996; 53: 617-624.
57. QUINN N, HALLETT M. Dose standardization of botulinum toxin. Lancet, 1989; 1: 964.
58. REPORT OF THE THERAPEUTICS AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY. The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology, 1990; 40: 1332-1336.
59. REPORT OF THE THERAPEUTICS AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology, 1994; 44: 2401-2403.
60. RIVEST J, LEES AJ, MARSDEN CD. Writer's cramp: treatment with botulinum toxin injections. Mov Disord, 1991; 6: 55-59.
61. ROSALES RL, ARIMURA K, TAKENAGE S, OSANNE M. Extrafusal and intrafusal muscle effects in experimental botulinum Toxin-A injection. Muscle Nerve, 1996; 19: 488-496.
62. SHARI CM, SANDERS I. Quantifying how location and dose of botulinum toxin injection affect muscle paralysis. Muscle Nerve, 1993; 16: 964-969.
63. SHEEAN GL, LEES AJ. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry, 1995; 59: 601-607.
64. SIMPSON LC. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev, 1981; 33: 155-188.
65. SIMPSON DM, ALEXANDER DN, O'BRIEN CF et al. Botulinum toxin A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology, 1996; 46: 1306-1310.
66. SLOOP RR, COLE BA, ESCUTIN RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology, 1997; 48: 249-253.
67. SNOW BJ, TSUI JKC, BHATT MH, VARELAS M, HASHIMOTO SA, CALNE DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol, 1990; 28: 512-515.
68. TROSCH RM, PULLMAN SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord, 1994; 9: 601-609.
69. TRUONG DD, RONTAL M, ROLNICK M, ARONSON AE, MISTURA K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope, 1991; 101: 630-634.
70. TSUI JK, EISEN A, STOESSL AJ, CALNE S, CALNE DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 1986; 2: 245-247.
71. TSUI JKC, BHATT M, CALNE S, CALNE DB. Botulinum toxin in the treatment of writer's cramp: A double-blind study. Neurology, 1993; 43: 183-185.
72. WHURR R, LORCH M, FONTANA H, BROOKES G, LEES AJ, MARSDEN CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry, 1993; 56: 526-530.
73. WISSEL J, KABUS R, KLEPSCH S et al. Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry, 1996; 61: 172-175.
74. ZUBER M. SEBALD M, BATHIEN N et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology, 1993; 43: 1715-1718.